The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Now, Moderna will deploy its mRNA technology to research vaccine approaches ... That starting point includes knowledge about viral structure, cell entry and the parts of the virus that might ...

assist in the development of refined molecular structure, and investigate how lipid nanoparticles used to deliver mRNA in the body could be improved. Moderna's chief executive, Stéphane Bancel ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of $23.00. Discover outperforming stocks and invest smarter ...